Bioventures Inc.

Zosano Pharma, Inc. to Provide Pipeline Updates at the 2009 AAPS Annual Meeting.
Computer Technology Journal; 11/19/2009; 1007 words; ...2245) About Zosano Pharma, Inc. Zosano Pharma, Inc. is a privately held pharmaceutical...Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments. For...Research, Other Scie, Zosano Pharma Inc. This article was prepared by...

Pulmatrix Closes $30.2 Million in Series B Financing.
Clinical Trials Week; 11/16/2009; 1328 words; ...ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation...CEO of Ore Pharmaceutical Holdings, Inc. and founding CEO of Pulmatrix and Robert...ARCH Venture Partners, and the Novartis Bioventures Fund. For additional information about...

Unigene Announces Financial Results for Third Quarter 2009.(Financial report)
Business Wire; 11/9/2009; 2037 words; ...BOONTON, N.J. -- Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene...Unigene received from Tarsa Therapeutics, Inc. ("Tarsa) on October 20, 2009 in...sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S. Simultaneously, Tarsa...

Publication No. WO/2009/094597 Published on July 30, Assigned to BioVentures, Celsis International for Nucleic Acid Probe Usage (American Inventors)
US Fed News Service, Including US State News; 11/9/2009; 634 words; ...use of nucleic acid probes to detect nucleotide sequences of interest in a sample. The patent has been assigned to BioVentures Inc., Murfreesboro, Tenn., and Celsis International plc, Chicago. According to an abstract posted by the World...

Lux Biosciences Completes $50 Million Series B Financing.
Chemicals & Chemistry Business; 11/6/2009; 1177 words; Lux Biosciences, Inc., a privately held biotechnology...investors in Lux Biosciences, HBM Bioventures, Novo A/S, Prospect Venture...Biosciences Lux Biosciences, Inc. is a privately held biotechnology...Technology, Lux Biosciences Inc. This article was prepared...